Dr. Ryan Case, PhD, Head of Clinical Medical Affairs at Neuroderm, a Mitsubishi Tanabe Pharma Corporation (MTPC), discusses the highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in Parkinson’s disease patients with motor fluctuations. ND0612 is a drug-device combination therapy – a 24 hours/day, continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD) for people with Parkinson’s disease experiencing motor fluctuations.
Ryan Case, PhD, has over 15 years of diverse experience developing innovative medical therapies for patients in need. While he’s worked in several therapeutics areas, he’s spent the last decade primarily focused on neuroscience and has a love for the field of Parkinson’s disease. He joined NeuroDerm, a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation, in 2017 and leads medical affairs activities for the company. With the recent positive results from the BouNDless trial, he’s excited to continue supporting the exploration of ND0612’s potential to be an effective, well-tolerated treatment option to better control motor fluctuations in patients with Parkinson’s disease.